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Abstract
Background: Despite a substantial reduction in in-hospital mortality, the long-term outcomes
of patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percu-
taneous transluminal coronary angioplasty (PTCA) remain uncertain. The main causes in-
clude progressive left ventricle (LV) remodelling and impaired LV systolic function with
a decreased ejection fraction (EF). B-type natriuretic peptide testing has recently emerged as an
innovative approach that might enhance the echocardiography-based risk stratification after
STEMI. The aims of the study included long-term echocardiographic assessment of LV func-
tion and remodelling in patients with STEMI treated with PTCA. Additionally, evaluation of
the N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma level utility was performed
to identify factors at patient discharge which would enable to predict LV dysfunction and
remodelling after STEMI at 6-month follow-up.
Methods: Echocardiography was performed in 98 patients  at discharge and at 6-month
follow-up. The diameters of the heart chambers and indices of LV systolic and diastolic function
were measured. Plasma levels of NT-proBNP were measured before PTCA and at 6 months.
Results: Primary PTCA successfully restored normal epicardial blood flow in the infarct-
related Artery (IRA) in 96 patients. At 6 months preserved LV systolic function (median EF
47.5%), decreased LV diastolic function with relaxation abnormalities (E/A < 1.0 and
IVRT > 105 ms) and no significant increase in left ventricular end-diastolic diameter (LVEDD)
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were observed in study population. Multivariate analysis identified low baseline NT-proBNP
level, low peak creatine phosphokinase (CPKmax) activity and high EF at discharge as powerful
independent predictors of preserved EF at 6 months. LVEDD at discharge, baseline NT-proBNP
level and CPKmax correlated with LVEDD at 6 months in the multiple regression model. In
multivariate analysis a high NT-proBNP level on admission and low LVEDD at discharge
were independent predictors of LVEDD change. Patient groups with reperfusion obtained
< and > 3.2 h from symptom onset (the median delay) did not differ with respect to IRA blood
flow, infarct size assessed as CPKmax and LVEDD at 6 months. A significant increase in EF
was noted only in patients with chest pain duration < 3.2 h. Time-to-treatment correlated with
NT-proBNP level at 6 months.
Conclusions: Successful primary PTCA in STEMI influences LV systolic function improve-
ment and effectively prevents LV remodelling at the 6-month follow-up. Low baseline
NT-proBNP, low CPKmax and high EF at discharge are powerful independent predictors of
preserved EF after 6 months. A high NT-proBNP level on admission and low LVEDD at
discharge predict a propensity for LV remodelling. A prolonged time-to-treatment of STEMI
results in a lack of significant long-term improvement in LV systolic function and does not seem
to have an impact on the occurrence of LV remodelling. (Folia Cardiol. 2006; 13: 605–619)
Key words: primary percutaneous transluminal coronary angioplasty,
echocardiography, post-infarct left ventricle remodelling, left ventricular
systolic and diastolic function, N-terminal pro-brain natriuretic peptide
Introduction
Despite a substantial reduction in in-hospital
mortality, the long-term outcomes of patients with
acute ST-elevation myocardial infarction (STEMI)
undergoing primary percutaneous transluminal co-
ronary angioplasty (PTCA) remain uncertain [1–3].
The main causes of poor prognosis after STEMI in-
clude progressive left ventricle (LV) remodelling
with chamber dilation, deformation and impaired LV
systolic function with a decreased ejection fraction
(EF) of below 40% [4–9]. Moreover, recent studies
have demonstrated that LV diastolic dysfunction in-
fluences progression of the chamber remodelling and
worsens patient prognosis after STEMI, irrespective
of impaired LV systolic function [10–13, 67–69].
According to the “open artery” theory, the pa-
tency of the infarction-related coronary artery (IRA)
plays a major role in LV remodelling following
STEMI [14, 15]. The restoration of blood flow in
the IRA reduces the extent of tissue necrosis and
diminishes infarct expansion, thus improving pa-
tient prognosis. The current theory of the “open
microvascular bed” states that preservation of LV
function after STEMI requires that both complete
coronary microvascular reperfusion and sustained
IRA and microcirculatory flow be obtained [16, 17].
In the literature there are no unequivocal data in-
dicating that primary PTCA prevents long-term
LV dysfunction more effectively than thrombolysis
[1, 6, 18–20]. The incidence of LV remodelling in
patients after STEMI treated with thrombolysis
reaches 35%, with normal IRA flow in 50–60% cases
[3, 4, 21]. Studies in patients with STEMI submitted
to primary PTCA procedures have shown that, despite
complete IRA patency being obtained in 80–95% cas-
es, as many as 30% patients may experience LV dila-
tation 6 months after infarction [3, 6, 7]. The reason
for this may be the lack of blood flow in the coro-
nary microcirculation observed in 30% patients (the
no-reflow phenomenon) in spite of the completely
restored IRA patency, resulting in more extensive
tissue necrosis and a higher incidence of complica-
tions [22–27]. Remodelling therefore seems to have
a stronger influence on long-term prognosis in pa-
tients with STEMI than does IRA patency.
The results of clinical studies have indicated
parameters, which, at the moment of discharge from
hospital, enable those STEMI patients to be iden-
tified who are at high risk of adverse LV remodel-
ling and dysfunction in the long term [18]. Currently
the main predictors of LV remodelling after myo-
cardial infarction are as follows: no application of
reperfusion therapy, a lack of IRA flow restoration
and normal microvascular perfusion after success-
ful primary PTCA, extensive necrosis, particularly
in cases of transmural infarction, anterior wall lo-
cation, symptoms of heart failure at admission,
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a restrictive type of transmitral flow in echocardiog-
raphy and administration of non-steroid anti-inflam-
matory drugs in the acute phase of STEMI [6, 17,
25, 28]. Among the factors said to favour long-term
LV function improvement after STEMI are complete
IRA reflow, absence of extensive tissue necrosis and
a smaller myocardial perfusion defect in contrast
echocardiography after reperfusion [6, 28, 29].
Simple, objective, non-invasive and widely ap-
plicable methods of predicting and detecting LV
dysfunction and remodelling in patients with STEMI
are currently under investigation. Echocardiogra-
phy is the fundamental tool in the non-invasive as-
sessment of LV morphology and function, although
it is not readily available and the investigator
requires considerable experience.
Evaluation of the N-terminal pro-brain natriu-
retic peptide (NT-proBNP) plasma level is a useful
tool in the detection of asymptomatic LV dysfunc-
tion as well as in diagnosing, prognosis assessment
and monitoring in symptomatic heart failure [30, 31].
Reports in the literature have raised hopes that
NT-proBNP could become a promising risk marker
of adverse clinical outcome in patients with STEMI
[2, 33–38].
The study presented here was performed in
a group of patients with STEMI submitted to pri-
mary PTCA. The aims of the study were:
— long-term echocardiographic assessment of LV
function and the incidence of LV remodelling;
— evaluation of NT-proBNP plasma level utility
in the diagnosis and prediction of LV remodel-
ling and dysfunction at 6-month follow-up;
— attempted identification of the factors which,
at the moment of discharge from hospital, en-
able LV dysfunction and remodelling after
STEMI to be predicted.
Methods
Design of the study and
characteristics of the study population
The study group consisted of 98 patients
(75 men and 23 women) admitted to the Department
of Cardiology and Internal Diseases of the Colle-
gium Medicum in Bydgoszcz with a diagnosis of
STEMI and designated to undergo primary PTCA
procedures. The study enrollment criteria were:
— typical anginal pain for at least 20 minutes;
— symptom onset less than 12 h before admission
to hospital and electrocardiographic features of
currently evolving STEMI (elevation of ST
segment ≥ 0.1 mV in at least two limb leads or
≥ 0.2 mV in at least two precordial leads).
Patients with the following features were ex-
cluded:
— a history of previous myocardial infarction;
— prior coronary revascularisation;
— cardiogenic shock at admission;
— bundle branch block;
— persistent atrial fibrillation;
— haemodynamically significant valvular heart
diseases;
— idiopathic cardiomyopathies.
The clinical characteristics of the patient pop-
ulation are presented in Table 1. The study proto-
col was accepted by the Bioethics Committee of the
Collegium Medicum in Bydgoszcz. Each patient
gave informed consent to participation in the study.
Coronary angiography and percutaneous
transluminal coronary angioplasty
Before intervention patients were administered
intravenous unfractionated heparin (100 IU/kg),
300 mg clopidrogel and 300 mg acetylsalicylic acid,
if the patient had not previously self-administered
these. Abciximab (blocker of glycoprotein IIb/IIIa
receptor) was administered at the discretion of the
invasive cardiologist. Additionally, 75 mg clopidogrel
Table 1. Clinical characteristics of the study
population (n = 98).
Age (years) 55.0 (50.0–63.0)
Sex (male/female) 75/23
Infarct location: anterior/inferior/ 55/42/1
/lateral wall
Time from symptom onset [h] 3.2 (2.2–4.5)
CPKmax [U/l] 1173.5 (451.0–2142.0)
Risk factors of
coronary artery disease
Body mass index [kg/m2] 26.6 (23.8–28.4)
Arterial hypertension 43 (44%)
Diabetes mellitus 13 (13%)
Current smokers 59 (60%)
History of smoking 23 (23%)
Positive family history 32 (33%)
LDL [mg/dl] 130.5 (104.0–160.0)
HDL [mg/dl] 44.0 (35.4–55.0)
Triglicerydes [mg/dl] 118.0 (90.0–177.0)
Cardiological history
Angina pectoris preceding infarction 64 (65%)
Medical treatment
Acetylsalicylic acid 98 (100%)
Statins 97 (99%)
ACE inhibitors 95 (97%)
Beta-blockers 96 (98%)
CPKmax — maximal creatine phosphokinease activity in the acute
phase of STEMI
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or 2 × 250 mg ticlopidine were administered for one
month following primary PTCA and 75 mg acetyl-
salicylic acid daily was prescribed for the lifetime
of each patient.
Coronary angiography and primary PTCA pro-
cedures were performed using the standard tech-
nique via the femoral artery with the aid of the CAS-
-10A device (Toshiba, Japan). Non-ionic low-osmo-
lar contrast media were applied. The optimal direct
effect of the intervention was assigned when no
residual stenosis or a stenosis of less than 20% of
the reference segment diameter was observed.
During angiography at least 5 left coronary artery
and 3 right coronary artery projections were taken
after a previous administration of 0.3 mg nitroglyc-
erine into the coronary vessels, if arterial pressure
was sufficient. Epicardial coronary flow was as-
sessed according to the Thrombolysis in Myocar-
dial Infarction (TIMI) scale and myocardial per-
fusion according to the TIMI Myocardial Perfusion
Grade (TMPG). A reliable evaluation of microvas-
cular perfusion in the area of the STEMI after pri-
mary PTCA was obtained in 27 patients.
Echocardiography
Transthoracic echocardiography was per-
formed in each patient on the day of discharge from
hospital (d) and after 6 months (f), using the Philips
SONOS 2000 and 7500 devices. The diameters of
the heart chambers and the following LV function
parameters were assessed during each procedure:
— parameters of the LV systolic function — LV
ejection fraction (EF, assessed through the
summation of discs from the 2 planes in
4-chamber and 2-chamber apical projections)
and the index of LV contractility-wall motion
score index (WMSI, expressed as the quotient
of the scores and the number of assessed seg-
ments, using the division of the left ventricle
muscle into 16 segments; normokinetic, hypok-
inetic and dyskinetic segments were assigned
scores of 1, 2, 3, and 4 points respectively);
— Doppler parameters of the LV diastolic func-
tion — peak velocity transmitral flow in its
early phase (E) and during atrial systole (A);
the E/A ratio; deceleration time (DT) of the
early transmitral flow, and the isovolumetric
relaxation time (IVRT).
An increase in left ventricle end-diastolic
diameter (LVEDD) of at least 10% at 6 months was
accepted as a marker of LV remodelling. An im-
provement in LV systolic function at the 6-month
follow-up was defined by statistically significant
changes in the following echocardiographic param-
eters: an EF increase and/or a WMSI decrease.
Diastolic LV dysfunction of the disturbed relaxation
pattern was diagnosed when the E/A ratio was lower
than one, and IVRT was greater than 105 ms. A re-
strictive pattern of transmitral flow was assigned
when the E/A ratio was greater than 2 and the DT
shorter than 130 ms.
Laboratory tests
NT-proBNP plasma level was evaluated at
baseline before primary PTCA (NT-proBNPd) and
at 6 months after STEMI (NT-proBNPf) through
ECLIA electrochemiluminescent assay (ELECSYS
1010 device, Roche Diagnostics, Mannheim, Ger-
many).
Statistical analysis
Calculations were performed using the Polish
version of the Statistica 7.1 software (StatSoft, Tul-
sa, USA). The usage of the Kolmogorov-Smirnov
test demonstrated that the analysed quantitative
variables were not normally distributed. Therefore,
quantitative variables were expressed as median
values and quartile ranges. Suitable non-paramet-
ric tests (Mann-Whitney, Kruskal-Wallis and Wil-
coxon) were used for comparison of median values
from quantitative dependent and independent var-
iables. For evaluation of correlations between sig-
nificant quantitative variables Spearman’s correla-
tion coefficient and test of significance for this co-
efficient were used. Qualitative variables were
expressed as the number of patients presenting the
given feature and the percentage of patients in the
group analysed. Unrelated qualitative variables
were compared using the c2 test with Yeats’s cor-
rection when suitable or the accurate Fisher test.
Analysis of related qualitative variables was per-
formed using the McNamara test. The influence of
numerous variables upon a quantitative variable was
assessed using the multiple regression model. Four
digits after the decimal point were presented for the
accuracy of the p-value. Values of p below 0.05 were
statistically significant. Accurate p-values were pre-
sented from within the range of 0.05–0.10 with
a trend toward statistical significance, whereas p-
values over 0.10 were treated as non-significant and
marked “NS”.
Results
Before primary PTCA procedures grade 0 or
1 flow according to the TIMI scale was observed in
the IRA in 69 patients (70%) (the left anterior de-
scending artery in 57% patients, left circumflex
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artery in 7% and right coronary artery in 36% pa-
tients). Successful primary PTCA interventions
were performed in all the patients studied, result-
ing in TIMI grade 3 flow in the IRA in 96 individu-
als (98%). Multivessel lesions were found in
45 patients (46%). In 63 (64%) abciximab was ad-
ministered and in 89 (91%) coronary stents were
implanted. Perfusion of the microcirculatory bed in
the area of the STEMI after primary PTCA was de-
scribed as grade 2 or 3 in the TMPG scale in 52%
patients.
During the 6-month follow-up period one de-
cease (1%) occurred and 2 cases of myocardial inf-
arction (2%) were noted, and in 6 patients (6%)
repeated coronary angioplasty was performed. An
insignificant increase in NT-proBNP plasma level
from 309.3 pg/ml (114.1–1226.5) to 344.5 pg/ml
(167.6–596.9) was observed during the follow-up
period.
The echocardiographic characteristics of the
study population on the day of discharge and at
6 months from STEMI are presented in Table 2. On
the day of discharge the following findings were
noted in the study group: increased diameter of the
left atrium (LA), normal LVEDD, no significant
impairment of LV contractility (EF of 45.0%) and
a lack of reliable evidence of significant diastolic
dysfunction of the LV (normal E/A ratio, slight pro-
longation of IVRT, no significant DT shortening).
After the 6-month follow-up period a significant in-
crease in EF and IVRT prolongation were observed
as well as a significant decrease in WMSI and the
E/A ratio with no significant changes in LVEDD and
LA. Analysis of echocardiographic parameters at
6 months in the group of patients studied revealed
preserved systolic LV function and abnormal diastol-
ic LV function in the form of an impaired relaxation
pattern (Table 2). At 6 months patients with median
or lower NT-proBNPd levels (i.e. £ 309.3 pg/ml)
demonstrated a significant decrease in WMSI (1.59
vs. 1.43 points; p = 0.0041), an increase in EF
(45.0% vs. 50.0%; p = 0.002) and a lower E/A ratio
(1.21 vs. 0.97; p = 0.0068). On the other hand, pa-
tients with NT-proBNPd levels greater than the
median value (i.e. > 309.3 pg/ml) had an increased
LVEDD (50.0 vs. 51.5 mm; p = 0.0964), significant
IVRT prolongation (112 vs. 119.5 ms; p = 0.0117),
a lower E/A ratio (0.92 vs. 0.88; p = 0.0985) and no
significant changes in EF and WMSI. After 6 months
of follow-up patient groups with NT-proBNPd lev-
els lower/equal to or greater than the median value
had a significantly different EF (50.0% vs. 45.5%;
p = 0.0176) and LA diameter (40.5 mm vs. 42.0 mm;
p = 0.0830). At 6 months after intervention patients
with NT-proBNPd levels £ 309.3 pg/ml had a sig-
nificantly higher EF than those with NT-proBNPd
> 309.3 pg/ml; there was no difference in EF be-
tween the two groups on the day of discharge
(45.0% vs. 44.0%; p = NS). After follow-up the EF
was significantly greater and the WMSI lower in the
group of patients with NT-proBNPf lower/equal to
median value (£ 344.5 pg/ml) as compared to the
group with NT-proBNPf greater than the median
value (50.0% vs. 45.0%; p = 0.0013 and 1.42 vs. 1.60;
p = 0.0004, respectively). The latter group had
a greater LVEDD and left ventricular end-systolic
diameter (LVESD) after 6 months (49.5 vs. 54.0 mm;
p = 0.0145 and 30.0 vs. 36.0 mm; p = 0.0000,
respectively).
Univariate analysis demonstrated the follow-
ing significant negative correlations: NT-proBNPd
and EFf (RS = –0.2877; p = 0.0072) (Fig. 1);
NT-proBNPf and EFd and EFf (RS = –0.28 and
RS = –0.41; p = 0.0072 and p = 0.0001, respectively)
(Fig. 2), and DTd and DTf (RS = – 0.33 and RS = – 0.21;
p = 0.0021 and p = 0.0552, respectively) (Fig. 3). Addi-
tionally, positive correlations were found between
NT-proBNPf and LVEDDf (RS = 0.2356; p = 0.0270)
and between WMSId (RS = 0.2743; p = 0.0101) and
WMSIf (RS = 0.4310; p = 0.0000). Multivariate
analysis revealed that independent predictors of the
EFf value were maximal creatine phosphokinease
Table 2. Echocardiographic characteristics of the
study population.
LAd [mm] 41.0 (38.5–45.0)
NS
LAf [mm] 41.0 (38.0–44.0)
LVEDDd [mm] 51.0 (48.5–55.0)
NS
LVEDDf [mm] 51.0 (48.0–57.0)
LVESDd [mm] 32.0 (29.0–37.5)
NS
LVESDf [mm] 33.0 (30.0–38.0)
WMSId [pts] 1.60 (1.42–1.81)
0.0005
WMSIf [pts] 1.44 (1.31–1.69)
LVEFd [%] 45.0 (40.0–50.0)
0.0027
LVEFf [%] 47.5 (43.0–53.0)
E/Ad (–) 1.1884 (0.8133–1.3966)
0.0015
E/Af (–) 0.9136 (0.7595–1.1940)
DTd [ms] 147.0 (129.0–172.0)
NS
DTf [ms] 144.0 (130.0–165.0)
IVRTd [ms] 112.0 (100.0–129.5)
0.0085
IVRTf [ms] 120.0 (110.0–130.0)
LA — diameter of left atrium; LVEDD — end-diastolic diameter of
left ventricle; LVESD — end-systolic diameter of left ventricle;
WMSI — wall motion score index of left ventricle; LVEF — left ven-
tricular ejection fraction; E — peak velocity of early transmitral flow;
A — peak velocity of transmitral flow during atrial systole; DT — decel-
eration time of the early transmitral flow; IVRT — isovolumetric relax-
ation time; d —parameter value at patient discharge; f — parameter
value after the 6-month follow-up period
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(CPKmax) and NT-proBNPd (an inversely proportional
relation) as well as EFd (directly proportional) (Ta-
ble 3). Independent predictors of LVEDDf value
were CPKmax, NT-proBNPd and LVEDDd (directly
proportional relations for each variable) (Table 4).
Independent predictors of increase in DLVEDD
after 6 months include LVEDDd (inversely proportion-
al) and NT-proBNPd (directly proportional) (Table 5).
When patient groups were compared in relation to
DLVEDD after 6 months (£ – 10%, n = 11; > – 10%
and < 10%, n = 69; ≥ 10%, n = 13), no significant
differences were found between the extent of tis-
sue necrosis assessed through enzymatic activity
(CPKmax of 1080.0 U/l vs. 1184.0 U/l vs. 1644.0 U/l;
p = NS) and between different time spans from pain
onset to reperfusion (4.0 h vs. 3.1 h vs. 2.3 h; p = NS).
Patients with the greatest LV dilatation after
6 months (≥ 10%) also had the highest NT-proBNPd
values of 508.1 pg/ml (114.7; 1458.0). A significant
difference in NT-proBNPd was observed between
the groups with DLVEDD £ –10%, > –10% and
< 10%. Moreover, higher NT-proBNPd was noted
in the group of patients with DLVEDD ≥ 10% as
compared to the group with DLVEDD £ – 10% after
6 months (Fig. 4). The highest levels of NT-proBNPf,
reaching 715.9 pg/ml (267.3; 1525.5), were observed
in patients with the greatest LV dilatation after
6 months. A trend towards higher levels of NT-proBNPf
was found in patients with DLVEDD ≥ 10% as com-
pared to those with DLVEDD > –10% and < 10%
after 6 months (Fig. 5). Patients with the greatest
LV dilatation on follow-up demonstrated a signifi-
cantly higher LAf, LVESDf, WMSId and WMSIf and
the lowest values for EFd and EFf (Table 6).
A comparison of the patient groups with the
time from symptom onset to reperfusion lower/
/equal to the median value (i.e. £ 3.2 h; n = 48; most
often STEMI of the anterior wall) with those with
time-to-treatment greater than the median (> 3.2 h;
n = 49) revealed no significant differences in prima-
ry PTCA efficacy in restoring IRA flow (grade 2 or
3 in the TIMI scale: 48 vs. 49 patients, respectively;
p = NS) and in enzymatic assessment of the extent
of necrosis (CPKmax of 1134.0 U/l vs. 1184.0 U/l, re-
spectively; p = NS). NT-proBNPd levels both  at dis-
charge and at follow-up were higher in patients with
Figure 1. Relation between baseline N-terminal pro-brain
natriuretic peptide level (NT-proBNP) and left ventricular
ejection fraction (EF) at 6 months after intervention.
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Figure 2. Relation between N-terminal pro-brain natriu-
retic peptide level (NT-proBNP) and left ventricular ejec-
tion fraction (EF), both at 6 months after intervention.
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Figure 3. Relation between deceleration time (DT) at
discharge and N-terminal pro-brain natriuretic peptide
level (NT-proBNP) at 6 months after intervention.
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a duration of infarct pain of over 3.2 h than in those
experiencing symptoms for £ 3.2 h (NT-proBNPd of
510.9 pg/ml vs. 208.7 pg/ml, respectively;
p = 0.0677; NT-proBNPf of 233.9 pg/ml vs. 131.3 pg/
/ml; p = 0.0864). Univariate analysis revealed a sig-
nificant positive correlation between the duration
of pain to the moment of reperfusion and NT-proBNPf
level (RS = 0.2640; p = 0.0135) as well as a trend
toward significance concerning NT-proBNPd (RS =
= 0.1824; p = 0.0835). A significant EF increase after
follow-up was noted exclusively in the group of pa-
tients with pain duration shorter than the median
(though the difference in EFf between the groups was
not significant and in both groups the value of the EFf
was greater than 45%) (Table 7). A significant de-
crease in the E/A ratio after 6 months was observed
only in patients with pain duration longer than the me-
dian (though the difference in E/Af between the
groups was not significant and both groups the valve
of E/Af was lower than one) (Table 7).
Table 3. Impact of variables from Tables 1 and 2 and baseline NT-proBNP level on LVEF after 6 months
in the multiple regression model.
Beta Beta Direction Beta p
coefficient  coefficient component coefficient
standard beta standard
error error
Entire study population (n = 93)
Model characteristics: R = 0.4437; R2 = 0.1969; p = 0.0001
Free term 51.4493 1.1741 0.0000
CPKmax [U/l] –0.3387 0.0988 –0.0016 0.0005 0.0009
NT-proBNPd [pg/ml] –0.3185 0.0988 –0.0014 0.0004 0.0018
Model including EF value at discharge
Model characteristics: R = 0.7695; R2 = 0.5921; p = 0.0000
Free term 20.1182 3.6847 0.0000
CPKmax [U/l] –0.1909 0.0736 –0.0009 0.0003 0.0112
NT-proBNPd [pg/ml] –0.1734 0.0735 –0.0008 0.0003 0.0208
LVEFd [%] 0.6529 0.0751 0.6466 0.0744 0.0000
CPKmax — maximal creatine phosphokinease activity in the acute phase of STEMI; NT-proBNP — N-terminal pro-brain natriuretic peptide; LVEF — left
ventricular ejection fraction; d — parameter value at patient discharge
Table 4. Impact of variables from tables 1 and 2 and baseline NT-proBNP level on LVEDD after
6 months in the multiple regression model.
Beta Beta Direction Beta p
coefficient coefficient component coefficient
standard beta standard
error error
Entire study population (n = 93)
Model characteristics: R = 0.3425; R2 = 0.1173; p = 0.0056
Free term 49.67848 0.988597 0.000000
CPKmax [U/l] 0.238100 0.103541 0.00090 0.000393 0.023984
NT-proBNPd [pg/ml] 0.268425 0.103541 0.00098 0.000377 0.011258
Model including LVEDD value at discharge
Model characteristics: R = 0.7004; R2 = 0.4906; p = 0.0000
Free term 11.8552 4.9696 0.0194
CPKmax [U/l] 0.1577 0.0803 0.0006 0.0003 0.0530
NT-proBNPd [pg/ml] 0.2150 0.0799 0.0008 0.0003 0.0087
LVEDDd [mm] 0.6179 0.0802 0.7483 0.0971 0.0000
CPKmax — maximal creatine phosphokinease activity in the acute phase of STEMI; NT-proBNP — N-terminal pro-brain natriuretic peptide;
LVEDD — end-diastolic diameter of left ventricle diameter; d — parameter value at patient discharge
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Discussion
In their study Bolognese et al. [6] observed at
long-term follow-up adverse LV remodelling after
STEMI in 30% patients submitted to primary PTCA
interventions, despite successful IRA patency res-
toration. This finding is comparable to the incidence
in LV remodelling in 34% patients who received
thrombolysis in the course of the GUSTO trial [8,
39, 40]. In the group of patients with STEMI un-
dergoing successful primary PTCA presented here
the significant LV dilatation was no observed at
6 months after intervention, and an LVEDD in-
crease of ≥ 10% as compared to the value on the
day of discharge was noted in 14% patients only.
Wita et al. [28] observed adverse LV remodelling
after 6 months in as many as 42.2% patients with
STEMI of the anterior wall successfully treated
with primary PTCA within 12 h of pain onset. The
relatively high incidence of LV remodelling after
STEMI treated with primary PTCA, resulting in the
complete flow restoration in the IRA, reported by
the above-mentioned authors in comparison with
the results of the present study indicates the influ-
ence of additional factors, including selection of
patient groups with more extensive tissue necro-
sis (STEMI of the anterior wall) [6, 28, 41], a lower
baseline EF [6, 28, 41] and longer duration of pain
until reperfusion [6, 28]. The importance of infarct
extent in risk stratification of LV remodelling is
Table 5. Impact of variables from Tables 1 and 2 and baseline NT-proBNP level on LVEDD after
6 months in the multiple regression model.
Beta Beta Direction  Beta p
coefficient  coefficient component coefficient
standard beta error
error standard
Entire study population (n = 93)
Model characteristics: R = 0.2385; R2 = 0.0569; p = 0.0279
Free term –0.015628 0.580939 0.978604
NT-proBNPd [pg/ml] 0.238535 0.106596 0.000675 0.000302 0.027916
Model including LVEDD value at discharge
Model characteristics: R = 0.3387; R2 = 0.1147; p = 0.0068
Free term 11.6090 5.0538 0.0241
NT-proBNPd [pg/ml] 0.2566 0.1042 0.0007 0.0003 0.0159
LVEDDd [mm] –0.2412 0.1042 -0.2268 0.0980 0.0231
NT-proBNP — N-terminal pro-brain natriuretic peptide; LVEDD — end-diastolic diameter of left ventricle diameter; d — parameter value at patient discharge
Figure 4. Comparison of baseline N-terminal pro-brain
natriuretic peptide levels (NT-proBNP) in patient groups
in relation to left ventricular end-diastolic diameter
(DLVEDD) change at 6 months after intervention.
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Figure 5. Comparison of N-terminal pro-brain natriure-
tic peptide levels (NT-proBNP) at 6 months in patient
groups in relation to left ventricular end-diastolic dia-
meter (DLVEDD) change at 6 months after intervention.
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Table 6. Comparison of selected echocardiographic parameters in patient groups in relation to LVEDD
change at 6 months after intervention.
Parameter DLVEDD £ –10% –10% < DLVEDD < 10% DLVEDD ≥ 10%
(n = 11)  (n = 69)  (n = 13) p
LAd [mm] 41.0 (36.0–42.0) 41.0 (38.0–44.0) 42.0 (40.0–46.0) NS
LAf [mm] 42.0 (36.0–44.0) 41.0 (37.0–43.0) 45.0 (42.0–51.0) 0.0060
LVEDDd [mm] 51.0 (51.0–55.0) 52.0 (49.0–55.0) 50.0 (46.0–52.0) NS
LVEDDf [mm] 46.0 (43.0–48.0) 51.0 (48.0–56.0) 58.0 (57.0–60.0) 0.0000
LVESDd [mm] 31.0 (29.0–35.0) 32.0 (29.0–38.0) 32.0 (28.0–34.0) NS
LVESDf [mm] 30.0 (27.0–33.0) 33.5 (30.0–37.0) 40.0 (33.0–44.0) 0.0092
WMSId [pts] 1.31 (1.25–1.60) 1.60 (1.42–1.81) 1.71 (1.58–1.81) 0.0226
WMSIf [pts] 1.38 (1.31–1.44) 1.44 (1.31–1.69) 1.60 (1.58–1.83) 0.0077
LVEFd [%] 48.0 (45.0–56.0) 45.0 (40.0–50.0) 40.0 (37.0–45.0) 0.0214
LVEFf [%] 48.0 (45.0–59.0) 49.0 (43.0–53.0) 45.0 (40.0–48.0) NS
E/Ad (–) 1.2222 (0.8929–1.3877) 1.2002 (0.8125–1.5781) 0.9263 (0.7272–1.2727) NS
E/Af (–) 1.1940 (0.7595–1.3019) 0.9205 (0.7609–1.1895) 0.8261 (0.7529–0.9750) NS
DTd [ms] 143.0 (114.0–200.0) 143.5 (129.0–167.0) 150.0 (140.0–180.0) NS
DTf [ms] 143.0 (140.0–170.0) 146.0 (130.0–165.0) 140.0 (130.0–172.0) NS
IVRTd [ms] 110.0 (100.0–133.0) 112.0 (100.0–122.0) 120.0 (92.0–130.0) NS
IVRTf [ms] 130.0 (112.0–150.0) 120.0 (110.0–131.5) 112.0 (104.0–130.0) NS
LA — diameter of left atrium; LVEDD — end-diastolic diameter of left ventricle diameter; LVESD — end-systolic diameter of left ventricle diameter;
WMSI — wall motion score index of left ventricle; LVEF — left ventricular ejection fraction; E — peak velocity of early transmitral flow; A — peak velocity
of transmitral flow during atrial systole; DT — deceleration time of the early transmitral flow; IVRT — isovolumetric relaxation time; d —  parameter
value at patient discharge; f — parameter value after the 6-month follow-up period
Table 7. Comparison of selected echocardiographic parameters in patient groups in relation to time-
-treatment change at 6 months after intervention
Parameter Pain duration £ median p Pain duration > median p p between
Pain duration £ 3.2 hours Pain duration > 3.2 hours groups
LAd [mm] 41.0 (38.0–44.0)
NS
41.5 (38.5–46.0)
NS
NS
LAf [mm] 41.0 (38.0–43.0) 41.5 (38.0–45.0) NS
LVEDdd [mm] 51.0 (48.0–56.0)
NS
51.0 (48.5–54.0)
NS
NS
LVEDDf [mm] 53.0 (48.0–57.0) 50.0 (48.0–57.0) NS
LVESDd [mm] 33.0 (29.0–38.0)
NS
31.5 (29.0–36.5)
NS
NS
LVESDf [mm] 34.0 (29.5–38.5) 32.5 (30.0–37.0) NS
WMSId [pts] 1.60 (1.42–1.81)
0.0061
1.58 (1.40–1.75)
0.0445
ns
WMSIf [pts] 1.50 (1.31–1.75) 1.44 (1.31–1.60) NS
LVEFd [%] 45.0 (39.0–48.0)
0.0006
46.0 (41.5–50.0)
NS
0.0758
LVEFf [%] 46.0 (43.0–52.0) 49.0 (43.0–54.0) NS
E/Ad (–) 1.0249 (0.778–1.2727)
NS
1.3303 (0.8929–1.600)
0.0018
0.0486
E/Af (–) 0.9136 (0.7529–1.1935) 0.9091 (0.7595–1.200) NS
DTd [ms] 150.0 (130.0–179.0)
NS
140.0 (120.0–163.0)
NS
NS
DTf [ms] 144.0 (130.0–167.0) 145.0 (130.0–165.0) NS
IVRTd [ms] 115.0 (100.0–130.0)
0.0157
112.0 (100.0–127.0)
NS
NS
IVRTf [ms] 130.0 (105.0–137.0) 120.0 (110.0–130.0) NS
LA — diameter of left atrium; LVEDD — end-diastolic diameter of left ventricle; LVESD — end-systolic diameter of left ventricle; WMSI — wall motion
score index of left ventricle; LVEF — left ventricular ejection fraction; E — peak velocity of early transmitral flow; A — peak velocity of transmitral flow
during atrial systole; DT — deceleration time of the early transmitral flow; IVRT — isovolumetric relaxation time; d — parameter value at patient discharge;
f — parameter value after the 6-month follow-up period
614
Folia Cardiol. 2006, Vol. 13, No. 7
www.foliacardiologica.eu
emphasised by the fact that in the reports cited
patients with LV remodelling had higher values for
the parameters characterising myocardial necrosis
[6, 28, 41], although these differences were insig-
nificant in the present study. We demonstrated
a significantly worse systolic function of the LV at
discharge from hospital and after 6 months in patients
who experienced LV remodelling on follow-up
(as compared to the group with no signs of such
a phenomenon). Nagaya et al. [41] stated that EF
and CPKmax correlate with LV remodelling 30 days
after infarction. Similarly, in his analysis of patients
with anterior wall STEMI treated with primary
PTCA, Katayama et al. [42] observed a higher inci-
dence of LV remodelling in patients with lower
baseline EF and diabetes. In the reports of Bolog-
nese et al. [6] and Wita et al. [28] LV remodelling
occurred only in patients with an initial EF value
below 40%. We found no relation between diabe-
tes and adverse LV remodelling in the observed
population. It should be noted, however, that only
13 patients in the study group had diabetes.
Despite the finding in one study of post-infarct
LV dilatation in 30% patients in whom intervention
took place within 6 h of pain onset [6], there are
emerging reports suggesting that a longer time to
invasive treatment has a significant influence on the
occurrence of LV remodelling following STEMI [10,
20, 43]. For thrombolytic therapy a linear depend-
ence was demonstrated between the time to the
advent of treatment, its angiographic effect and the
prognosis in patients with STEMI [40]. No advan-
tage of invasive treatment over fibrinolysis in the
prevention of LV remodelling after STEMI was
observed when the time from symptom onset was
less than 3 h [20] and when the delay in coronary
intervention as compared to fibrinolysis was over
60 min [44, 45]. Some authors emphasise that
a longer time to reperfusion may have a powerful
impact upon LV function and dilatation in patients
with STEMI successfully treated with primary
PTCA within 3–12 h of the onset of infarct pain [1, 2,
20, 23, 46–48]. Araszkiewicz et al. [49] demonstrated
that early primary PTCA intervention (up to 220 min
after pain onset) in patients with STEMI of the
anterior wall significantly reduces the risk of LV
remodelling in the 6 months after infarction. This
finding indicates a decreasing LV volume in patients
with pain duration until reperfusion of less than 3 h
as compared to those treated more than 6 h after-
wards, in whom the chamber volume increases [49].
Sheiban et al. [47] found no significant differences
in the incidence of LV remodelling when patients
with STEMI were successfully treated with prima-
ry PTCA not later than 2 h after symptom onset. In
the present study no significant relationship was
found between duration of infarct pain and indices
of LV remodelling. This observation could be influ-
enced by a short mean time to reperfusion (median
of 3.2 h) and the fact that only 6 patients in the pop-
ulation described were submitted to primary PTCA
after more than 6 h. Several other factors mentioned
in the literature could also be beneficial in the
progress of LV remodelling in our study. These are
TIMI 3 flow in the IRA before primary PTCA, found
in 19% patients [36, 50, 51], the occurrence of
angina pectoris before STEMI [52] and the wide
administration of agents known for their anti-re-
modelling action, including ACE inhibitors and
b-blockers.
Both Bolognese et al. [6] and Wita et al. [28]
demonstrated that patients with LV remodelling
experienced severe cardiovascular complications
significantly more often in long-term follow-up, in-
cluding death, a further myocardial infarction or an
in-hospital stay due to heart failure. The low inci-
dence of LV remodelling, short reperfusion delay,
complete IRA patency restoration, preservation of
systolic function and an absence of important diasto-
lic LV disturbances could be the reasons for the low
incidence of the above-mentioned complications in
our patient population at 6 months after STEMI.
Other factors concerning primary PTCA interven-
tion which could decrease the incidence of IRA re-
occlusion and restenosis and influence clinical out-
comes in the long term in the group of patients pre-
sented include a high rate of coronary stent
implantation (91%) and wide administration of ab-
ciximab (64%) [22, 36, 52–54]. However, in his
study, despite administration of GP IIb/IIIa recep-
tor blockers in 71% and IRA stent implantation in
99% patients, Wita et al. [28] noted a higher mor-
tality at 6 months (3%) and significant IRA resten-
osis in 36% persons in follow-up coronary angiog-
raphy performed after 6 months.
The study presented here supports the hypoth-
esis that successful IRA patency restoration
through primary PTCA in patients with STEMI
enables LV systolic function to be preserved at the
time of discharge and improved in the 6 months
following acute myocardial infarction. This could
result from great primary PTCA efficacy in restor-
ing IRA patency and thus in decreasing the extent
of necrosis, reversion of myocardial stunning and
restoration of the hibernated myocardial function [28].
Acording to our results CPKmax activity is a feature
of great importance in predicting deterioration in
LV systolic function at 6 months after infarction.
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Many authors emphasise that a longer time to
reperfusion has a strong influence on LV dysfunc-
tion in patients with STEMI submitted to primary
PTCA [46, 47, 55]. Such a relationship was observed
by Antoniucci et al. [56] in the group of high risk
patients (STEMI of the anterior wall, cardiogenic
shock on admission, heart rate over 100/min, age
over 70 years). De Luca et al. [57] demonstrated
that primary PTCA delay in STEMI correlates with
worse myocardial perfusion, a greater infarct area
and a higher mortality rate after one year. Araszk-
iewicz et al. [49] found a significantly higher EF both
3 days and 6 months following STEMI in patients
with anterior wall infarction submitted to invasive
treatment before 3 h from pain onset as compared
to those treated after more than 6 h. The present
study confirms that early (before 3.2 h) primary
PTCA treatment of STEMI makes an important
contribution to the improvement of the LV systolic
function in long-term follow-up. Our observations
are compatible with the results published by Agati
et al. [55], who showed that in cases of delayed
reperfusion through primary PTCA there may be no
improvement in LV systolic function but the benefi-
cial effect of intervention on LV remodelling may be
preserved. This observation may result from a dif-
ferent time of evolution of subendocardial and sub-
epicardial necrosis, which may lead to infarct expan-
sion and LV remodelling in cases of a long occluded
segment [55].
In the present study, patients with lower
NT-proBNP levels after 6 months had lesser ad-
verse post-infarct LV remodelling. LV dilatation in
long-term follow-up occurred only in patients with
NT-proBNP levels greater than the median value
(over 344.5 pg/ml) at 6 months. These patients ex-
perienced no improvement in LV systolic function
either. The above-mentioned findings confirm the
significant relations existing between LVEDD and
NT-proBNP, both measured after 6 months. This
finding is of great importance with regard to data
from the literature which emphasise the occurrence
of a second BNP peak or sustained BNP increase
(over 3–4 weeks after STEMI) in the development
of LV remodelling [58, 59] or LV systolic dysfunc-
tion [60] in long-term follow-up. Nagaya et al. [59]
described patients with STEMI and a persistent
increase in BNP level at 7 days after infarction as
the population at highest risk of LV remodelling at
6 months. Nilsson et al. [61] demonstrated that
a persistent high level of plasma NT-proBNP is the
strongest predictor of remodelling after one year
from the acute myocardial infarction [60]. During
the 6-month follow-up period of patients with STEMI
Wita et al. [28] found greater NT-proBNP levels
after 5 days in individuals with adverse LV remod-
elling; univariate analysis showed a correlation
between this feature and the occurrence of remod-
elling. Nagaya et al. [41] demonstrated that only
BNP plasma level assessed on the day of discharge
and evaluation of CPK and EF in the acute phase of
infarction correlate with LV remodelling 30 days af-
ter infarction. A relationship between an increased
NT-proBNP plasma level at the time of admission
to hospital and the risk of remodelling was found
both in patients with STEMI receiving thrombolysis
[32] and in those undergoing primary PTCA [62, 63].
Grabowski et al. [64] observed a greater incidence
of the no-reflow phenomenon in patients with STE-
MI submitted to primary PTCA in whom high lev-
els of plasma NT-proBNP were found at admission.
Multivariate analysis in the present study demon-
strated that NT-proBNP level on admission and
LVEDD on discharge in patients with STEMI un-
dergoing primary PTCA constitute an important and
independent predictor of adverse LV remodelling
at 6 months.
We demonstrated that both baseline NT-proBNP
levels and those measured after 6 months in pa-
tients with STEMI submitted to primary PTCA sig-
nificantly correlate with EF value in long-term fol-
low-up. Moreover, improved LV systolic function
at 6 months after STEMI was observed exclusively
in patients with lower baseline NT-proBNP plasma
levels (below 309.0 pg/ml). Patients with a NT-proBNP
level lower than the median value (344.5 pg/ml) at
6 months had significantly better systolic function
in the long term. The results presented are com-
patible with the report from Richards et al. [33], who
demonstrated a close relationship between BNP
plasma levels on days 1–4 of the in-hospital stay and
the EF value in the acute phase of STEMI (day 1–4)
as well as at 3–5 months after infarction [33]. Oth-
er authors have also observed a negative correla-
tion between BNP plasma level and EF [28]. Clini-
cal studies in patients with STEMI have demon-
strated the prognostic value of decreased EF.
However, there is still no certainty that it is the best
predictor of mortality and symptomatic heart failure.
Richards et al. [43] performed an analysis on 666
patients with acute myocardial infarction treated in
the majority of cases by thrombolysis. They found
that increased BNP levels and an EF below 40% are
of independent prognostic value for a 3-year risk of
decease, heart failure and myocardial infarction. It
is noteworthy that BNP was an important and in-
dependent predictor of death and heart failure in
the subgroup with preserved LV systolic function
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(EF over 40%) and that at the same time the EF
value had no prognostic importance [43]. To sum
up, the NT-proBNP plasma level on admission to
hospital may in clinical practice predict the occur-
rence of remodelling and decreased LV systolic
function in patients with STEMI submitted to pri-
mary PTCA in whom the EF on the day of discharge
is normal.
On the basis of the results of the present study,
it has been demonstrated that in patients with STEMI
the following are the most important independent
predictors of the LV systolic function in the long
term: EF on discharge, maximal CPK activity in the
acute phase of STEMI and NT-proBNP level before
primary PTCA. In the study of Bolognese et al. [6]
predictors of LV remodelling included high CPK ac-
tivity, multivessel disease and abnormal baseline
LV systolic parameters. In our study, in contrast,
these features played no part in the model of LV
remodelling prediction. Among numerous evaluat-
ed parameters, Wita et al. [28] described the fol-
lowing as independent markers: proximal occlusion
of the left anterior descending coronary artery, no
resolution of ST elevation in ECG and high CK-MB
levels but not a low EF. Both authors emphasise
the role of disturbances in the microvascular coro-
nary bed in the prediction of adverse LV remodel-
ling after infarction [17, 28]. Bolognese et al. [17]
reported that the most important factor predicting
LV dilatation, decease or propensity for adverse
cardiovascular incidents (such as a further infarc-
tion or heart failure) over a 46-month follow-up
period in patients with STEMI undergoing primary
PTCA is the perfusion index, assessed through con-
trast echocardiography. The incidence of LV remod-
elling in the group with abnormal myocardial per-
fusion reached 63% as compared to 11% in patients
with normal perfusion, and as many as 42% patients
died or needed hospitalisation as a result of heart
failure within 5 years [17]. Myocardial perfusion,
assessed through angiography according to the
MBG or TMPG scale, may be the marker of the real
efficacy of the intervention in patients with STEMI
undergoing primary PTCA [17, 65, 66]. Evidence
is emerging that the MBG index in patients with
acute myocardial infarction after primary PTCA
correlates with the infarct area assessed enzymat-
ically and is a better predictor of long-term mortal-
ity, incidence of adverse cardiovascular events or
deterioration of LV function than the Killip class,
TIMI scale or EF value [14]. In our study the ang-
iographic index of myocardial perfusion (TMPG)
was assessed only in 27% patients. The fact, there-
fore, that there was no normal perfusion (TMPG
score 0–1) in 48% of these patients, despite TIMI 3
flow restoration in IRA, is of limited value. Wita et
al. [28] had similar results and found preserved
myocardial perfusion (defined as MBG scale grade
2–3) only in 53.3% patients, despite flow restora-
tion in IRA and administration of GP IIb/IIIa recep-
tor blockers in 71.1% persons. In this study the val-
ue of the MBG index in predicting the occurrence
of LV remodelling was doubtful since MBG scale
2–3 perfusion was noted in patients both with and
without adverse LV remodelling [28].
Some reports indicate the good correlation be-
tween plasma BNP level and mortality in patients with
STEMI. This introduces an additional parameter, in-
dependent of the known factors (clinical data, ECG find-
ings, troponin), into the range of popular risk assess-
ment scores [70, 71]. The value of this parameter is
concerned both in increased BNP and NT-proBNP lev-
els on admission to hospital [63] and in persistent in-
creased or augmenting NT-proBNP levels over 72 h
or within 3–4 weeks of myocardial infarction [58]. The
absence of a significant increase in the plasma
NT-proBNP level in the present study population dur-
ing 6 months follow-up could be an indicator of low
risk of adverse cardiovascular events in this period.
Study limitations
The limitations of the study are the relatively
short duration of follow-up, the small population
and the lack of routine coronary angiography dur-
ing follow-up and angiographic evaluation of micro-
vascular perfusion in all the patients enrolled. Ap-
plication of new methods of LV function and myo-
cardial perfusion assessment (using contrast
echocardiography and tissue Doppler echocardiog-
raphy) would enable a more reliable evaluation of
primary PTCA efficacy to be obtained. Assessment
of plasma NT-proBNP levels on the day of dis-
charge could also prove useful with reference to
the reports in the literature which emphasise the
significance of a second plasma NT-proBNP peak
on days 5–7 after STEMI.
Conclusions
1. Successful primary PTCA in patients with STE-
MI results in significant improvement in the LV
systolic function and prevents adverse LV re-
modelling in a 6-months follow-up.
2. Low baseline NT-proBNP, low CPKmax activity
and high EF at discharge are powerful independ-
ent predictors of EF preservation 6 months
after intervention.
3. High baseline NT-proBNP and small LVEDD
at discharge are prognostic factors of LV re-
modelling.
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4. A longer delay in reperfusion treatment is as-
sociated with a lack of LV systolic function im-
provement and has no significant impact on the
occurence of LV remodelling.
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